Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors
Research report (imported) 2017 - Max Planck Institute for Molecular Genetics
Colorectal carcinomas (CRC) are clinically challenging tumors. To identify novel predictive biomarkers of the therapeutic response, the OncoTrack consortium recruited 106 CRC patients for establishing a biobank of organoids and xenografts models analysed by sequencing and tested in a pre-clinical platform. This unique resource generated a compendium of data for advancing our understanding of CRC. Linking molecular patterns with drug response profiles identified novel biomarkers, including a signature outperforming RAS/RAF mutations in predicting sensitivity to the EGFR inhibitor cetuximab.